Two new H2-receptor antagonists, famotidine (Pepcid PM - MSD), and nizatidine (Axid - Lilly) were marketed last year for the treatment of peptic ulceration. Many would feel that the existing and well-tried drugs are satisfactory. Do these latest competitors offer therapeutic advantages? Are they needed or simply ‘me-too’ drugs in a large and lucrative market?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.